Sagent Pharmaceuticals, Inc. Acquires Rights to Multi-Chamber Syringe Technology and Launches Device Division

Sagent Pharmaceuticals, Inc. Acquires Rights to Multi-Chamber Syringe Technology and Launches Device Division

SCHAUMBURG, Ill., Sept. 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced the acquisition of Infusive Technologies' proprietary, patented, multi-chamber, sequential dose syringe technology.

Sagent's innovative, dual-chamber syringe enables the sequential administration of two separate intravenous (IV) medications with a single syringe push, thereby replacing two syringes with one. The benefits of this single delivery capability include increasing the speed and ease of drug administration; reducing risk of hospital acquired infection by reducing the number of connections; lowering the risk of drug administration or sequence errors, and quicker delivery of emergency medicines requiring an immediate sequential flush. The unique dual-chamber syringe can accommodate lyophilized, powder or liquid formulations in the front chamber combined with diluents, saline or heparin flush in the rear chamber.

"We believe that this dual-chamber syringe technology has far reaching benefits which will allow health care providers to deliver multiple drugs more quickly and more safely than with multiple syringes," said Jeffrey M. Yordon, chairman, founder and chief executive officer of Sagent Pharmaceuticals. "The simplicity and functionality of this device yield near-term opportunities for use with both proprietary and multi-source pharmaceutical products. We welcome Infusive's Chief Executive Officer, Bradley C. Robinson, to Sagent in his role as president of Sagent's newly created device division, Sagent Technologies. The creation of Sagent Technologies marks an important milestone for the company, as it enhances our ability to provide a broad range of differentiated product offerings to healthcare providers."

"We look forward to introducing a pre-filled format of the dual chamber syringe to Sagent's U.S. customers in 2009," said Bradley C. Robinson. "Syringes based on our unique, patented technologies have the potential to dramatically improve the delivery of IV medications, reduce the risk of medical error and hospital-acquired infection while at the same time lowering costs for healthcare providers. Infusive was immediately impressed that Sagent not only is committed to providing quality IV medications, but also to providing IV medications in delivery systems designed to enhance effectiveness and improve patient safety. I look forward to joining Jeff and the team at Sagent and to quickly make this exciting new device available to patients and caregivers."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.